TW201625637A - 經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案 - Google Patents

經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案 Download PDF

Info

Publication number
TW201625637A
TW201625637A TW104140600A TW104140600A TW201625637A TW 201625637 A TW201625637 A TW 201625637A TW 104140600 A TW104140600 A TW 104140600A TW 104140600 A TW104140600 A TW 104140600A TW 201625637 A TW201625637 A TW 201625637A
Authority
TW
Taiwan
Prior art keywords
compound
formula
alkyl
days
administered
Prior art date
Application number
TW104140600A
Other languages
English (en)
Chinese (zh)
Inventor
尼蘇 劉
法蘭茲卡 席格
羅伯特 佛瑞克
奧勒福 多爾
銳 維納西亞
Original Assignee
拜耳製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拜耳製藥公司 filed Critical 拜耳製藥公司
Publication of TW201625637A publication Critical patent/TW201625637A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104140600A 2014-12-03 2015-12-03 經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案 TW201625637A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14196142 2014-12-03
EP15160671 2015-03-24
EP15161215 2015-03-26
EP15165541 2015-04-28

Publications (1)

Publication Number Publication Date
TW201625637A true TW201625637A (zh) 2016-07-16

Family

ID=54754665

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104140600A TW201625637A (zh) 2014-12-03 2015-12-03 經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案

Country Status (2)

Country Link
TW (1) TW201625637A (fr)
WO (1) WO2016087488A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2021260443A1 (fr) * 2020-06-24 2021-12-30 Bayer Aktiengesellschaft Associations de 2,3-dihydroimidazo[1,2-c]quinazolines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
SG10201710539QA (en) * 2013-04-08 2018-01-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Also Published As

Publication number Publication date
WO2016087488A1 (fr) 2016-06-09

Similar Documents

Publication Publication Date Title
US9902727B2 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP3043778B1 (fr) Compositions pharmaceutiques contenant du refametinib
US9675616B2 (en) Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
JP2014513704A (ja) Ｍｋｎｋ１キナーゼ阻害剤としてのアミノ置換イミダゾピリダジン
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
WO2014020043A1 (fr) Combinaisons pour le traitement du cancer
US9730943B2 (en) Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
CN105008364A (zh) 取代的咪唑并哒嗪
TW201625637A (zh) 經胺醇取代之２，３－二氫咪唑［１，２－ｃ］喹唑啉衍生物之給藥方案
EP2848246A1 (fr) Compositions pharmaceutiques contenant du refametinib
US20180022750A1 (en) 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines
TW201625261A (zh) ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療白血病之用途
TW201642867A (zh) ４－（４－氟－２－甲氧基苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三□－２－胺於治療多發性骨髓瘤之用途
TW201501712A (zh) （ｒｓ）－ｓ－環丙基－ｓ－（４－｛［４－｛［（１ｒ，２ｒ）－２－羥基－１－甲基丙基］氧基｝－５－（三氟甲基）嘧啶－２－基］胺基｝苯基）磺醯亞胺於治療特定腫瘤之用途